Marshall Wace, LLP Castle Biosciences Inc Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Castle Biosciences Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 220,797 shares of CSTL stock, worth $6.24 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

220,797

Previous 212,036 4.13%

Holding current value

$6.24 Million

Previous $4.62 Million 36.42%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$17.4 - $31.47 $152,441 - $275,708	8,761 Added 4.13%	220,797 $6.3 Million
Q2 2024 Aug 14, 2024	BUY	$18.84 - $24.94 $2.15 Million - $2.85 Million	114,104 Added 116.51%	212,036 $4.62 Million
Q1 2024 May 15, 2024	BUY	$18.06 - $25.3 $957,757 - $1.34 Million	53,032 Added 118.11%	97,932 $2.17 Million
Q4 2023 Feb 14, 2024	BUY	$12.19 - $22.43 $547,331 - $1.01 Million	44,900 New	44,900 $968,000
Q2 2022 Aug 15, 2022	BUY	$16.0 - $45.99 $166,400 - $478,296	10,400 New	10,400 $228,000
Q1 2021 May 17, 2021	SELL	$58.92 - $97.33 $1.18 Million - $1.95 Million	-19,995 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$43.6 - $73.05 $674,404 - $1.13 Million	15,468 Added 341.68%	19,995 $1.34 Million
Q3 2020 Nov 16, 2020	SELL	$38.47 - $52.03 $1.33 Million - $1.81 Million	-34,692 Reduced 88.46%	4,527 $234,000
Q2 2020 Aug 13, 2020	BUY	$27.28 - $43.01 $659,848 - $1.04 Million	24,188 Added 160.92%	39,219 $1.48 Million
Q1 2020 May 15, 2020	BUY	$23.08 - $35.53 $346,915 - $534,051	15,031 New	15,031 $448,000

Others Institutions Holding CSTL

# of Institutions

199

Shares Held

25.9M

Call Options Held

303K

Put Options Held

30.3K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $743M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Castle Biosciences Inc Transaction History